Clinical Trial Update: Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing QMF149 to salmeterol/fluticasone in COPD completed with results posted, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QMF149 (mometasone/formoterol)
• Salmeterol xinafoate / fluticasone propionate (Salmeterol xinafoate / fluticasone propionate)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: COPD | Phase 2 | Status: COMPLETED | Results posted: 2014-11-17